Drug EfficacyGanaxolone treatment shows rapid seizure cessation, with a median timing of 5 minutes, offering hope for patients with drug-resistant seizure disorders.
Market PotentialAnalysts highlight significant market potential for Marinus, with commercial opportunities for ganaxolone in seizure treatment possibly exceeding $500 million.
Regulatory ApprovalZtalmy, an oral form of ganaxolone, receives approval in the U.S. and EU for CDKL5 deficiency disorder, signaling a new treatment option on the market.